ClinicalTrials.gg
CompletedNCT04527991TROPiCS-04Updated Jun 2, 2026Results posted

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Phase 3 interventional study of Sacituzumab Govitecan-hziy and Paclitaxel in Locally Advanced or Metastatic Unresectable Urothelial Cancer, sponsored by Gilead Sciences. Completed at 234 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
711
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

02

Conditions studied

  • Locally Advanced or Metastatic Unresectable Urothelial Cancer
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with documented or locally advanced unresectable UC defined as

    • Tumor (T) 4b, any node (N) or
    • Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.
  • (ECOG) performance status (PS) score of 0 or 1.
  • Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled.

    • Individuals with recurrence or progression ≤12 months following completion of cisplatin-containing chemotherapy given in the /adjuvant setting may utilize that to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These individuals must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible.
    • Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the neo- adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study.
    • Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.

      -- Cisplatin ineligibility is defined as meeting one of the following criteria:

      • \< 60 mL/min
      • Grade ≥ 2 Audiometric Hearing Loss
      • Grade ≥ 2 Peripheral Neuropathy
      • (NYHA) Class III heart failure
      • ECOG PS ≥ 2
    • Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study
    • Individuals who have progressed after receiving enfortumab vedotin in prior lines of therapy, and individuals who are either ineligible or unable to tolerate enfortumab vedotin therapy, are eligible to enroll in the study
    • Individuals who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
  • Individuals with previously treated may participate in the study provided they have stable central nervous system disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using >20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.
  • Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation ( ≥ 9 g/dL, (ANC) ≥1,500/mm\^3, and ≥100,000/µL).
  • Adequate hepatic function ( ≤1.5x institutional (IULN), (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dL).

Docetaxel will only be option in TPC arm for individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also >2.5 x IULN.

  • Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g. Modification of Diet in Renal Disease () equation).
  • Females of must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Females of childbearing potential must be willing to use 2 methods of or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study drug. Individuals of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >2 years.
  • Males must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.

Key Exclusion Criteria:

  • Females who are pregnant or lactating.
  • Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC) within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals participating in observational studies are eligible.
  • Have received prior chemotherapy for UC with any available standard of care (SOC) therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is approved and is commercially available).
  • Have not recovered (i.e., ≤ Grade 1) from adverse events due to previously administered chemotherapeutic agent.
  • Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.
  • Note: If Individuals received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.
  • Have previously received topoisomerase 1 inhibitors.
  • Have an active second .
  • Note: Individuals with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
  • Have active cardiac disease, defined as:

    • Myocardial infarction or unstable angina pectoris within 6 months of C1D1.
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of prolongation.
    • NYHA Class III or greater congestive heart failure or of \<40%.
  • Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment.
  • Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification).
  • Have known history of (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism.
  • Have active Virus (HBV) or Virus (HCV). In individuals with a history of HBV or HCV, individuals with a detectable viral load will be excluded.
  • Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  • Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan-hziy or unable or unwilling to receive the doses specified in the protocol.
  • Have inability to complete all specified study procedures for any reason.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
711 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy (SG)

    Participants will receive 10 mg/kg of SG intravenously (IV) on Day 1 and Day 8 of each 21-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion is met.

    Drug: Sacituzumab Govitecan-hziy

  • Active comparator
    Treatment of Physician's Choice

    Participants will receive 1 of 3 standard-of-care chemotherapeutic options, as determined by the investigator prior to randomization, and will continue to receive the same treatment for the duration of the study until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion is met. Paclitaxel 175 mg/m\^2 IV on Day 1 of every 21-day cycle or Docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day cycle or Vinflunine 320 mg/m\^2 IV on Day 1 of every 21-day cycle (in countries where vinflunine was approved and was commercially available).

    Drug: Paclitaxel · Drug: Docetaxel · Drug: Vinflunine

Interventions

  • Administered intravenously

    Also known as: IMMU-132, Trodelvy™, GS-0132

  • Administered intravenously

    Also known as: Taxol®

  • Administered intravenously

    Also known as: Taxotere®

  • Administered intravenously

    Also known as: Javlor ®

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as time from the date of randomization to the date of death, regardless of cause. Kaplan-Meier (KM) estimates were used for analysis.

    Time frame: Up to 42 months

Secondary outcomes

  1. Progression-Free Survival (PFS) by Investigator Assessment

    PFS was defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per response evaluation criteria in solid tumors (RECIST) v1.1 criteria as determined by investigator assessment, or death regardless of cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). KM estimates were used for analysis.

    Time frame: Up to 42 months

  2. Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)

    PFS is defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per RECIST v1.1 criteria as determined by BICR, or death regardless of cause, whichever occurs first. PD was defined in outcome measure (OM) #2. KM estimates were used for analysis.

    Time frame: Up to 42 months

  3. Objective Response Rate (ORR) by Investigator Assessment

    ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as best overall response (BOR) as assessed by investigator assessment. CR was defined as disappearance of all target lesions. PR was defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Percentages were rounded off.

    Time frame: Up to 42 months

  4. Objective Response Rate (ORR) by BICR

    ORR was defined as the percentage of participants who achieved a CR or PR as BOR as assessed by BICR. CR and PR are defined in OM#4. Percentages were rounded off.

    Time frame: Up to 42 months

  5. Clinical Benefit Rate (CBR) by Investigator Assessment

    CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or stable disease (SD) for ≥ 6 months, per RECIST v1.1, as assessed by investigator assessment. SD is defined as Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; PD was defined in OM#2; BOR, CR and PR are defined in OM#4. Percentages were rounded off.

    Time frame: Up to 42 months

  6. Clinical Benefit Rate (CBR) by BICR

    CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or SD for ≥ 6 months, per RECIST v1.1, as assessed by BICR. PD was defined in OM#2; BOR, CR and PR are defined in OM#4; SD was defined in OM#6. Percentages were rounded off.

    Time frame: Up to 42 months

  7. Duration of Objective Tumor Response (DOR) by Investigator Assessment

    DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by investigator assessment, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.

    Time frame: Up to 42 months

  8. Duration of Objective Tumor Response (DOR) by BICR

    DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by BICR, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.

    Time frame: Up to 42 months

  9. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. The SAE was defined as any untoward medical occurrence that at any dose which was fatal (results in death) or life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or an important medical event. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.

    Time frame: From first dose up to 33.6 months

  10. Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities

    A laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time of postbaseline up to and including the date of last study drug dose plus 30 days. Severity grades were defined by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death. Percentages were rounded off.

    Time frame: From first dose up to 33.6 months

  11. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score

    The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.

    Time frame: Baseline (Day 0)

  12. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score

    The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.

    Time frame: Cycle 5 Day 1; Cycle length = 21 days

07

Results

Posted Jun 2, 2026

Participant flow

Participants were enrolled at study sites in Asia, Australia, Europe, and North America.

Participant flow — Overall Study
MilestoneSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Started355356
Completed00
Not completed355356
Withdrew: Death293297
Withdrew: Other (not specified)3731
Withdrew: Withdrawal of consent2127
Withdrew: Lost to follow-up41

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as time from the date of randomization to the date of death, regardless of cause. Kaplan-Meier (KM) estimates were used for analysis.

Time frame:
Up to 42 months
Reported as:
Median · months
Overall Survival (OS)
monthsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Overall Survival (OS)10.3 (9.1 to 11.8)9.0 (7.5 to 9.7)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Log Rank · p = 0.0870 (P value is from a stratified log-rank test, adjusted for randomization stratification factors as reported in Electronic Case Report Form (eCRF).) · Stratified hazard ratio: 0.86 · 95% CI 0.73 to 1.02Hazard ratio and 95% confidence intervals (CIs) were calculated using the Cox model adjusted for randomization stratification factors as reported in eCRF.
SecondaryProgression-Free Survival (PFS) by Investigator Assessment

PFS was defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per response evaluation criteria in solid tumors (RECIST) v1.1 criteria as determined by investigator assessment, or death regardless of cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). KM estimates were used for analysis.

Time frame:
Up to 42 months
Reported as:
Median · months
Progression-Free Survival (PFS) by Investigator Assessment
monthsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Progression-Free Survival (PFS) by Investigator Assessment4.0 (2.9 to 4.2)2.9 (2.8 to 3.5)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Stratified Log-rank · p = 0.0117 (P value was from a stratified log-rank test, adjusted for randomization stratification factors from eCRF.) · Stratified hazard ratio: 0.81 · 95% CI 0.68 to 0.95Hazard ratio and 95% CIs were calculated using the Cox model adjusted for randomization stratification factors from eCRF.
SecondaryProgression-Free Survival (PFS) by Blinded Independent Central Review (BICR)

PFS is defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per RECIST v1.1 criteria as determined by BICR, or death regardless of cause, whichever occurs first. PD was defined in outcome measure (OM) #2. KM estimates were used for analysis.

Time frame:
Up to 42 months
Reported as:
Median · months
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)
monthsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)4.2 (3.8 to 4.5)3.6 (2.9 to 4.2)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Stratified Log-rank · p = 0.1095 (P value was from a stratified log-rank test, adjusted for randomization stratification factors from eCRF.) · Stratified hazard ratio: 0.86 · 95% CI 0.72 to 1.03Hazard ratio and 95% CIs were calculated using the Cox model adjusted for randomization stratification factors from eCRF.
SecondaryObjective Response Rate (ORR) by Investigator Assessment

ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as best overall response (BOR) as assessed by investigator assessment. CR was defined as disappearance of all target lesions. PR was defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Percentages were rounded off.

Time frame:
Up to 42 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by Investigator Assessment
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Objective Response Rate (ORR) by Investigator Assessment19.7 (15.7 to 24.2)15.7 (12.1 to 19.9)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Cochran-Mantel-Haenszel · p = 0.1594 · Stratified odds ratio: 1.32 · 95% CI 0.90 to 1.95P value, odds ratio, and 2-sided CI were calculated based on Cochran-Mantel-Haenszel statistics adjusted for randomization stratification factors.
SecondaryObjective Response Rate (ORR) by BICR

ORR was defined as the percentage of participants who achieved a CR or PR as BOR as assessed by BICR. CR and PR are defined in OM#4. Percentages were rounded off.

Time frame:
Up to 42 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by BICR
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Objective Response Rate (ORR) by BICR22.5 (18.3 to 27.2)13.8 (10.4 to 17.8)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Cochran-Mantel-Haenszel · p = 0.0022 · Stratified odds ratio: 1.84 · 95% CI 1.24 to 2.73P value, odds ratio, and 2-sided CI were calculated based on Cochran-Mantel-Haenszel statistics adjusted for randomization stratification factors.
SecondaryClinical Benefit Rate (CBR) by Investigator Assessment

CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or stable disease (SD) for ≥ 6 months, per RECIST v1.1, as assessed by investigator assessment. SD is defined as Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; PD was defined in OM#2; BOR, CR and PR are defined in OM#4. Percentages were rounded off.

Time frame:
Up to 42 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) by Investigator Assessment
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Clinical Benefit Rate (CBR) by Investigator Assessment31.5 (26.7 to 36.7)21.9 (17.7 to 26.6)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Cochran-Mantel-Haenszel · p = 0.0032 · Stratified odds ratio: 1.67 · 95% CI 1.19 to 2.34P value, odds ratio, and 2-sided CI were calculated based on Cochran-Mantel-Haenszel statistics adjusted for randomization stratification factors.
SecondaryClinical Benefit Rate (CBR) by BICR

CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or SD for ≥ 6 months, per RECIST v1.1, as assessed by BICR. PD was defined in OM#2; BOR, CR and PR are defined in OM#4; SD was defined in OM#6. Percentages were rounded off.

Time frame:
Up to 42 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) by BICR
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Clinical Benefit Rate (CBR) by BICR29.9 (25.1 to 34.9)20.5 (16.4 to 25.1)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · Cochran-Mantel-Haenszel · p = 0.0034 · Stratified odds ratio: 1.68 · 95% CI 1.19 to 2.37P value, odds ratio, and 2-sided CI are calculated based on Cochran-Mantel-Haenszel statistics adjusted for randomization stratification factors.
SecondaryDuration of Objective Tumor Response (DOR) by Investigator Assessment

DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by investigator assessment, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.

Time frame:
Up to 42 months
Reported as:
Median · months
Duration of Objective Tumor Response (DOR) by Investigator Assessment
monthsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Duration of Objective Tumor Response (DOR) by Investigator Assessment7.1 (5.8 to 9.0)5.8 (3.7 to 7.0)
SecondaryDuration of Objective Tumor Response (DOR) by BICR

DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by BICR, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.

Time frame:
Up to 42 months
Reported as:
Median · months
Duration of Objective Tumor Response (DOR) by BICR
monthsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Duration of Objective Tumor Response (DOR) by BICR7.2 (6.3 to 8.4)6.5 (5.2 to 8.3)
SecondaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. The SAE was defined as any untoward medical occurrence that at any dose which was fatal (results in death) or life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or an important medical event. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.

Time frame:
From first dose up to 33.6 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
TEAE99.495.0
TESAE53.032.6
SecondaryPercentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities

A laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time of postbaseline up to and including the date of last study drug dose plus 30 days. Severity grades were defined by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death. Percentages were rounded off.

Time frame:
From first dose up to 33.6 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities
percentage of participantsSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities68.636.8
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score

The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.

Time frame:
Baseline (Day 0)
Reported as:
Mean · score on scale
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score
score on scaleSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Functional Scales: Physical Functioning: Baseline74.6 ± 21.3475.5 ± 21.81
Global Health Status / Quality of life (QoL) : Baseline59.6 ± 21.3962.2 ± 21.76
Symptom Scales / Items: Pain : Baseline34.3 ± 31.8331.7 ± 28.45
Symptom Scales / Items: Fatigue : Baseline35.8 ± 24.3437.4 ± 25.43
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score

The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.

Time frame:
Cycle 5 Day 1; Cycle length = 21 days
Reported as:
Least squares mean · score on scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score
score on scaleSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Functional Scales: Physical Functioning: Change from Baseline at Cycle 5 Day 1-7.3 (-10.1 to -4.5)-8.4 (-11.4 to -5.4)
Global Health Status / QoL : Change from Baseline at Cycle 5 Day 1-1.6 (-4.6 to 1.4)-1.6 (-4.8 to 1.6)
Symptom Scales / Items: Pain : Change from Baseline at Cycle 5 Day 1-4.2 (-8.2 to -0.3)-1.5 (-5.7 to 2.7)
Symptom Scales / Items: Fatigue : Change from Baseline at Cycle 5 Day 15.6 (2.0 to 9.1)7.6 (3.8 to 11.4)
Statistical analysis
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · MMRM · p = 0.5638 · Least square (ls) mean difference: 1.1 · 95% CI -2.5 to 4.7LS mean, their difference (SG vs TPC) and P value for change from baseline was based on mixed-effects model for repeated measures (MMRM) model including all visits up to and including cycle 5 day 1 (C5D1).
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · MMRM · p = 0.9944 · Ls mean difference: 0.0 · 95% CI -3.9 to 3.9LS mean, their difference (SG vs TPC) and P value for change from baseline was based on MMRM model including all visits up to and including C5D1.
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · MMRM · p = 0.3007 · Ls mean difference: -2.7 · 95% CI -7.8 to 2.4LS mean, their difference (SG vs TPC) and P value for change from baseline was based on MMRM model including all visits up to and including C5D1.
  • Sacituzumab Govitecan-hziy (SG) vs Treatment of Physician's Choice · MMRM · p = 0.3871 · Ls mean difference: -2.0 · 95% CI -6.6 to 2.6LS mean (SG vs TPC), their difference and P value for change from baseline were based on MMRM model including all visits up to and including C5D1.

Adverse events

Collected over Up to 42 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacituzumab Govitecan-hziy (SG)305/355 (85.9%)185/349 (53%)341/349 (97.7%)
Treatment of Physician's Choice310/356 (87.1%)110/337 (32.6%)303/337 (89.9%)
Most frequent serious events
Showing 10 of 182
Most frequent serious events
EventSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
Febrile neutropeniaBlood and lymphatic system disorders37/34915/337
DiarrhoeaGastrointestinal disorders30/3496/337
NeutropeniaBlood and lymphatic system disorders16/3496/337
Urinary tract infectionInfections and infestations16/34911/337
SepsisInfections and infestations12/3494/337
PyrexiaGeneral disorders11/3497/337
Neutropenic sepsisInfections and infestations10/3493/337
Neutrophil count decreasedInvestigations10/3494/337
Acute kidney injuryRenal and urinary disorders10/3493/337
Septic shockInfections and infestations9/3493/337
Most frequent other events
Showing 10 of 46
Most frequent other events
EventSacituzumab Govitecan-hziy (SG)Treatment of Physician's Choice
DiarrhoeaGastrointestinal disorders189/34963/337
AnaemiaBlood and lymphatic system disorders186/349116/337
NauseaGastrointestinal disorders157/34959/337
AlopeciaSkin and subcutaneous tissue disorders138/349113/337
FatigueGeneral disorders109/34976/337
ConstipationGastrointestinal disorders104/34966/337
AstheniaGeneral disorders99/34974/337
Decreased appetiteMetabolism and nutrition disorders94/34958/337
NeutropeniaBlood and lymphatic system disorders92/34923/337
VomitingGastrointestinal disorders79/34920/337

Baseline characteristics

The Intent-to-treat (ITT) Analysis Set included all participants who have been randomized to the trial.

Age, Categorical
Age, Categorical(Participants)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
<=18 years000
Between 18 and 65 years133131264
>=65 years222225447
Age, Continuous
Age, Continuous(years)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
Mean66 ± 9.167 ± 10.167 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
Female7177148
Male284279563
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
Race — American Indian or Alaska Native011
Race — Asian9282174
Race — Black or African American011
Race — Native Hawaiian or Other Pacific Islander000
Race — White194188382
Race — Other or More Than One Race112
Race — Not Collected6883151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
Ethnicity — Not Hispanic or Latino279271550
Ethnicity — Hispanic or Latino8614
Ethnicity — Not Collected6879147
Region of Enrollment
Region of Enrollment(Participants)Sacituzumab Govitecan-hziy (SG)Treatment of Physician's ChoiceTotal
France6981150
Spain365288
China424183
South Korea382765
United Kingdom272855
Italy222547
Belgium202242
Greece161430
Australia171128
Germany131326
Canada14519
Austria6511
Taiwan3710
United States6410
Georgia369
Israel639
Portugal437
Singapore415
Sweden235
Ireland123
Bulgaria022
Croatia112
Switzerland202
Turkey202
Hong Kong101
08

Study locations

234 sites
  • Mayo Clinic - Arizona
    Phoenix, Arizona 85054, United States
  • UCLA Hematology/ Oncology
    Los Angeles, California 90095, United States
  • University of California Irvine (UCIMC)
    Orange, California 92868, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Boca Raton Clinical Research Global USA - Plantation
    Plantation, Florida 33322, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oklahoma Cancer Specialists and Research Institute (OCSRI)
    Tulsa, Oklahoma 74104, United States
  • Penn State Hershey Cancer Institute
    Hershey, Pennsylvania 17033, United States
  • Thompson Oncology Group - Knoxville Downtown
    Knoxville, Tennessee 37916, United States
  • University Cancer Specialists - Knoxville
    Knoxville, Tennessee 37920, United States
  • Harold C. Simmons Comprehensive Cancer Center
    Dallas, Texas 75390, United States
  • Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Seattle Cancer Care Alliance (SCCA)
    Seattle, Washington 98109, United States
  • Summit Cancer Centers
    Spokane, Washington 99208, United States
  • Chris O'Brien Lifehouse
    North Ryde, New South Wales 2109, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Icon Cancer Centre Wesley
    Auchenflower, Queensland 4066, Australia
  • Southern Adelaide Local Health Network Incorporated
    Bedford Park, South Australia 5042, Australia
  • Ashford Cancer Centre Research - ICON Cancer Centre Adelaide
    Kurralta Park, South Australia 5037, Australia
  • ICON Cancer Centre Hobart
    Hobart, Tasmania 7001, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Sunshine Hospital
    Saint Albans, Victoria 3021, Australia
  • Liverpool Hospital
    Nedlands, Western Australia 6009, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Universitätsklinik für Innere Medizin Graz
    Graz, 8036, Austria
  • Ordensklinikum Linz GmbH Barmherzige Schwestern
    Linz, 4010, Austria
  • Krankenhaus Der Barmherzigen Bruder Wien
    Vienna, 1020, Austria
  • Grand Hôpital De Charleroi - Notre Dame
    Charleroi, 6000, Belgium
  • Az Maria Middelares Ghent
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, B-4000, Belgium
  • Multiprofile Hospital for Active Treatment Heart and Brain EAD
    Pleven, 5800, Bulgaria
  • Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District
    Sofia, 1233, Bulgaria
  • Cross Cancer Institute
    Edmonton, T6G 1Z2, Canada
  • qeii health sciences centre - VG site
    Halifax, B3H 2Y9, Canada
  • Juravinski Hospital and Cancer Centre
    Hamilton, L8V 5C2, Canada
  • London Health Sciences Centre
    London, N6A 4G5, Canada
  • Jewish General Hospital
    Montreal, H3T 1E2, Canada
  • McGill University Health Centre
    Montreal, H4A 3J1, Canada
  • R.S. McLaughlin Durham Regional Cancer Centre
    Oshawa, L1G 2B9, Canada
  • Princess Margaret Cancer Centre
    Toronto, M5G 2M9, Canada
  • British Columbia Cancer Agency-Vancouver Centre
    Vancouver, V5Z 4E6, Canada
  • Peking University First Hospital
    Beijing, 100034, China
  • Chinese People's Liberation Army General Hospital - 301 Hospital
    Beijing, 100039, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Chinese Academy of Medical Sciences Cancer Hospital
    Beijing, 100730, China
  • 1st Hospital Jilin University
    Changchun, 130021, China
  • Hunan Cancer Hospital - Xiangya Hospital - Central South University
    Changsha, 410013, China
  • West China Hospital Sichuan University
    Chengdu, 610041, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    Chengdu, 610072, China
  • Chongqing University Cancer Hospital
    Chongqing, 400030, China
  • The First Affiliated Hospital of Fujian Medical University
    Fujian, 350005, China
  • Union Hospital of Fujian Medical University
    Fuzhou, 350001, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, 510060, China
  • Zhejiang Provincial People's Hospital - Zhaohui
    Hangzhou, 310014, China
  • Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Anhui Provincial Cancer Hospital
    Hefei, 230031, China
  • Qilu Hospital of Shandong University
    Jinan, 250012, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, 110042, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, 300060, China
  • Affiliated Tumor Hospital of Xinjiang Medical University
    Ürümqi, 830000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430030, China
  • Clinical Hospital Centre Split
    Split, 21000, Croatia
  • Clinical Hospital Centre "Sestre Milosrdnice"
    Zagreb, 10000, Croatia
  • University Hospital Centre Zagreb
    Zagreb, Croatia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Urocentrum Praha
    Prague, 120 00, Czechia
  • Ramsay Health Clinic Belharra
    Bayonne, France
  • CHU Saint Andre
    Bordeaux, 33075, France
  • Centre Hospiltalier Universitaire Brest - Hôpital Morvan
    Brest, 29200, France
  • Centre Francois Baclesse
    Caen, 14076, France
  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
  • Centre Georges- Francois Leclerc
    Dijon, 21000, France
  • Centre Hospitalier Departemental Vendee
    La Roche-sur-Yon, 85925 CEDEX 9, France
  • Centre Oscar Lambret
    Lille, 59000, France
  • Centre Leon Berard
    Lyon, 69373, France
  • Institut Régional du Cancer de Montpellier ICM Val d' Aurelle
    Montpellier, 34090, France
  • Centre Antoine Lacassagne
    Nice, 06189, France
  • Centre Hospitalier Universitaire de Nimes
    Nîmes, 30029, France
  • Hôpital Européen Georges-Pompidou
    Paris, 75015, France
  • Centre Eugene Marquis
    Rennes, 35042, France
  • Centre Hospitalier Privé Saint-Grégoire
    Saint-Grégoire, 35760, France
  • Les Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
  • Hôpital Foch
    Suresnes, 92150, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France

Showing the first 100 of 234 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Loriot Y, Grivas P. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025 May;36(5):561-571. doi: 10.1016/j.annonc.2025.01.011. Epub 2025 Feb 11. PubMed 39934055 ↗
  • Grivas P, Tagawa S, Bellmunt J, De Santis M, Duran I, Goebell PJ, et al. TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy. [Poster TPS498]. American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU); 2021 February 11-13; Virtual meeting.
  • Grivas P., Powles T., Vulsteke C., Gross-Goupil M., Park S. et al. LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis. Annals of Oncology, Volume 35, Supplement 4, S1505-S1507, December 2024.
  • Vulsteke C, Grivas P, Tagawa ST, Bellmunt J, De Santis M, Duran I, et al. TROPiCS-04: Study of Sacituzumab Govitecan (SG) in Patients (Pts) With Locally Advanced (LA) Unresectable or M etastatic Urothelial Cancer (mUC) That Has Progressed After Prior Platinum (PLT) and Checkpoint Inhibitor (CPI) Therapy. [Poster TPS582]. American Society of Clinical Oncology Genitourinary (ASCO-GU); 2022 February 17-19; Annual Meeting.
  • Powles T, Tagawa ST, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Bangs R, Loriot Y, Grivas P. A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract. Future Oncol. 2025 Dec;21(28):3593-3610. doi: 10.1080/14796694.2025.2579003. Epub 2025 Nov 23. PubMed 41277126 ↗
  • Klumper N, Cox A, Sjodahl G, Roghmann F, Bolenz C, Hartmann A, Grunwald V, Faltas BM, Holzel M, Eckstein M. Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. Nat Rev Urol. 2025 May;22(5):256-267. doi: 10.1038/s41585-024-00951-2. Epub 2024 Oct 29. PubMed 39472646 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jul 2025, 53 months.

Results were first posted in Jun 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 27, 2020
StartActual
Jan 13, 2021
Primary completionActual
Jul 4, 2025
CompletionActual
Jul 4, 2025
Results first posted
Jun 2, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04527991
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 27, 2020
Start date
Jan 13, 2021
Primary completion
Jul 4, 2025
Completion
Jul 4, 2025
Results posted
Jun 2, 2026
Last update
Jun 2, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion